Btai stock forecast also hinges on broader biotech ETF

BTAI stock forecast also hinges on broader biotech ETF flows, given the stock’s high correlation with sector benchmarks like IBB and XBI. If you want to know who really controls BioXcel Therapeutics, Inc. ( NASDAQ:BTAI ), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 47% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). For detailed information about BTAI stock, go to TipRanks’ Stock Analysis page . Long-term BTAI stock forecast scenarios show potential market cap expansion if the firm secures commercial partnerships in Europe or Asia.